Hidden Metabolic Loop Lets Liver Cancer Dodge Immunotherapy
A newly discovered enzyme-driven feedback cycle helps liver tumors suppress immunity and resist checkpoint blockade — and blocking it may help.
Summary
Researchers identified a key enzyme, AARS1, that drives a self-reinforcing cycle allowing liver cancer cells to suppress the immune system and resist immunotherapy. AARS1 chemically modifies a protein called ATF6 using lactate — a byproduct of the tumor's own sugar metabolism — stabilizing it and triggering production of a molecule called kynurenine. Kynurenine recruits regulatory T cells, which are immune cells that dampen anti-tumor responses. Those T cells then release a signal that ramps up more sugar metabolism in the tumor, producing more lactate and feeding the whole cycle again. Crucially, blocking AARS1 with beta-alanine — a common supplement — broke this cycle and made tumors respond better to PD-1/PD-L1 immunotherapy drugs in mouse models.
Detailed Summary
Liver cancer, or hepatocellular carcinoma (HCC), is one of the deadliest cancers worldwide, partly because tumors become highly skilled at evading the immune system and resisting modern immunotherapies. Understanding how tumors do this is essential to developing better treatments.
This study from top Chinese medical centers examined why HCC tumors with high glycolytic activity — meaning they burn large amounts of glucose — tend to be especially aggressive and immunotherapy-resistant. Using single-cell and spatial transcriptomics, the researchers identified AARS1, an enzyme normally involved in protein synthesis, as a key driver of both tumor growth and immune suppression.
The mechanistic findings are striking. AARS1 acts as a lactyltransferase, using lactate produced by glycolysis to chemically tag a transcription factor called ATF6. This modification stabilizes ATF6, which then activates TDO2, an enzyme that converts tryptophan into L-kynurenine. Kynurenine is a well-known immunosuppressive metabolite that promotes regulatory T cell (Treg) expansion. Tregs then secrete eNAMPT, a signal that boosts glycolysis in tumor cells — generating more lactate, which fuels more ATF6 lactylation, closing the loop. Patients with high AARS1 expression had worse prognosis and greater immunotherapy resistance.
Critically, pharmacological inhibition of AARS1 using beta-alanine disrupted this cycle in mouse models and restored tumor sensitivity to PD-1/PD-L1 checkpoint blockade immunotherapy.
Caveats apply: the mechanistic work relies heavily on mouse models, and human clinical validation of AARS1 inhibition is pending. The summary is based on the abstract only, so full methodological details and the breadth of human data cannot be assessed. Nonetheless, this work identifies a compelling, druggable target linking tumor metabolism to immune evasion in liver cancer.
Key Findings
- AARS1 enzyme is overexpressed in liver tumors and correlates with poor prognosis and immunotherapy resistance.
- AARS1 modifies ATF6 with lactate, stabilizing it and activating tryptophan-to-kynurenine conversion via TDO2.
- L-kynurenine drives regulatory T cell expansion, suppressing anti-tumor immune responses.
- Tregs feed back by secreting eNAMPT, amplifying tumor glycolysis and sustaining the AARS1-driven loop.
- Beta-alanine blocked AARS1 activity and sensitized tumors to PD-1/PD-L1 immunotherapy in mice.
Methodology
The study used integrated single-cell and spatial transcriptomic analyses stratified by glycolytic activity in HCC tumors, combined with hepatocyte-specific AARS1 knockout mouse models. Clinical correlation was performed using 18F-FDG PET/CT imaging to quantify glycolytic flux in patients, alongside survival and immunotherapy response data.
Study Limitations
This summary is based on the abstract only; full methodology, sample sizes, and human data breadth cannot be independently verified. The key mechanistic and therapeutic findings are from mouse models and require clinical validation. The role of beta-alanine as an AARS1 inhibitor in humans remains untested.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: